# Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

> **NCT07291037** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 400 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Datopotamab deruxtecan (Dato-DXd)
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT07291037
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-31
- **Primary completion:** 2029-01-29
- **Final completion:** 2029-01-29
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07291037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07291037, "Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07291037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*